ReviewFrontiers in immunology2025
Fine-tuning immunity: ubiquitin-dependent regulation of interleukin-17A expression by Th17 cells.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The ubiquitin-editing enzyme A20 (TNFAIP3): mechanisms of activation, biological function, diseases and therapeutic targets.Molecular biomedicine · 2026Review
- [Ubiquitination-mediated regulation of T cell homeostasis and autoimmune diseases].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that plays a pivotal role in immune responses, particularly in the pathogenesis of various autoimmune diseases and infections. Recent advances have highlighted the significance of post-translational modifications, particularly ubiquitination, in regulating IL-17A expression and IL-17A receptor signaling pathways. Here, we summarize the intricate relationship between IL-17A and ubiquitination, exploring how ubiquitin-mediated processes influence IL-17A production, receptor signaling, and downstream effector functions. We provide insights into the potential therapeutic implications of targeting IL-17A and its ubiquitination pathways in inflammatory diseases and autoimmune disorders. A clear understanding of this relationship could pave the way for novel strategies in immune modulation, potentially enhancing management and treatment efficacy in various human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.